Thursday, October 28, 2021

Tag: COVID-19

Two Hundred and Fifty Shows and 12 years Later

Twelve years ago, Vince Caruso  had an idea to provide a forum for the bold and visionary companies. He named it    NewToTheStreet.com (NTTS),  shared...

Biotech Benefits from UpListing – $7.00 Target Price from Think Equity

PetVivo Holdings, Inc. (NASDAQ: PETV), is new to the NASDAQ and has historically been a light trader in terms of volume.  September however marked...

Merck’s Molnupiravir Data Accelerates Tollovir Development

Todos Medical Inc. (OTCMKTS: TOMDF) just announced a major positive update in their development of Tollovir, their COVID-19 antiviral drug. This breaking story uncovered...

Uplisted to NASDAQ Today! Patent Protection and Security in the Healthcare...

Some of the largest healthcare companies in the world include UnitedHealth Group Inc. (NYSE: UNH), Pfizer Inc. (NYSE: PFE), and Abbvie Inc. (NYSE: ABBV). These companies are currently sitting above or close to their all-time-high.

CytoDyn’s (CYDY) Long-Hauler Trial a Resounding Success: Clear Pathway to Approval...

Clinically Significant Data in 18 of 24 SymptomsSeeking Breakthrough Therapy Designation in Long-Haulers and CancerDefinitive timeline for HIV BLA Filing by October 2021Dosing of...

5 Small-Cap Pharma Stocks to Buy in June

While the COVID-19 pandemic has cast doubt on many investments, pharma stocks have never looked better. The need for novel treatments and therapies is...

Celledex gaining traction on experimental Cancer Vaccine while Avalon Globocare paves...

In other ongoing research looking at cancer vaccines, the Cancer Research Institute, in partnership with the Parker Institute for Cancer Immunotherapy, is studying a combination of a vaccine with the adjuvants Flt3 ligand and poly-ICLC plus the checkpoint inhibitor nivolumab (Opdivo) and standard-of-care radiation in castrate-resistant prostate cancer. Results are expected in the next six to 12 months, said Jill O’Donnell-Tormey, chief executive officer and director of scientific affairs at the Cancer Research Institute.

Marble Arch Research Report Healixa, Inc. (OTC Pink: EMOR)

COMPANY SUMMARY On June 22, 2020, Emerald Organic Products Inc. (OTCPK: EMOR), a Nevada Corporation, changed its name to Healixa Inc., to reflect the company’s...

Some Experts worry about Next-Generation COVID-19 Vaccines , while they know...

We may find out whether this is going to be a problem sooner than you’d think. Moderna NASDAQ: MRNA is working with the National Institute of Allergy and Infectious Diseases — which helped it design its original Covid vaccine — to test an updated version of its vaccine that targets the variant first spotted in South Africa, B.1.351. That variant appears to be able to evade immune responses triggered by earlier versions of the virus.

Healthcare Technology Disruptor Obtains National Reach

Look at Healixa, Inc. (OTC Pink: EMOR)